News

Nuclear Medicine Europe logo

July 10, 2024

University of Missouri Research Reactor joins Nuclear Medicine Europe

Mizzou’s collaboration will strengthen global radiopharmaceutical and imaging supply.

a man moves a sample in the containment pool

June 27, 2024

Pioneering progress in cancer treatments

From its research reactor to revolutionary therapies, Mizzou’s innovations are shaping the future of precision medicine.

Michael Hoehn II

June 4, 2024

Michael Hoehn II named inaugural program director of NextGen MURR

Hoehn will lead Mizzou’s transformational initiative to build a new state-of-the-art research reactor that will expand medical isotope production.

Grace Liles works in a chemistry lab

May 7, 2024

Making a positive impact

When University of Missouri senior Grace Liles enrolled at Mizzou, one of the world’s leading research institutions, she joined the chemistry fraternity Alpha Chi Sigma.

The outside of the Molecular Imaging and Theranostics Center

April 5, 2024

MITC administratively realigns under MU Research Reactor 

The change will allow for consistent staff training, a cohesive and vibrant safety culture and dedicated facility support.

A graphic representing radioisotopes in the liver

April 3, 2024

Innovative yttrium-90 radioisotopes revolutionize liver cancer treatment

Yttrium-90 radioisotopes produced at the University of Missouri Research Reactor are extending and improving the lives of patients with liver cancer.

A student works in the lab

Feb. 27, 2024

Adding a radioisotope to the toolkit for saving lives

A pair of University of Missouri researchers study terbium-161 with the hope that one day it could be the next major radioisotope produced to treat cancer.

Pluvicto being handled by a radio pharmacist.

Dec. 14, 2023

MU Health Care pilots breakthrough treatment for prostate cancer

Treatment uses radioisotopes produced in the University of Missouri Research Reactor.

A shipping tech moves a shipment into a van

Dec. 8, 2023

MU Research Reactor announces commercial shipments of breakthrough radioisotope for cancer treatment

The University of Missouri Research Reactor (MURR) is the only U.S. supplier of the radioisotope, produced using a propriety process developed at MURR.

A graphic of NextGen MURR

Nov. 7, 2023

Tiny atoms, big impact: How the MU Research Reactor is saving and improving lives in Missouri and around the globe

NextGen MURR initiative will expand the University of Missouri’s capacity to produce medical isotopes that will be used in advanced cancer treatments for decades to come.